E
SRPT icon

Ergoteles’s Sarepta Therapeutics SRPT Stock Holding History

Ergoteles’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-23,502
Closed -$2.69M – 737
2023
Q2 		$2.69M Sell
23,502
-11,873
-34% -$1.53M 0.13% 202
2023
Q1 		$4.88M Sell
35,375
-24,545
-41% -$3.18M 0.19% 92
2022
Q4 		$7.76M Buy
59,920
+50,632
+545% +$5.87M 0.29% 83
2022
Q3 		$1.03M Sell
9,288
-31,661
-77% -$3.19M 0.04% 472
2022
Q2 		$3.07M Buy
+40,949
New +$3.01M 0.09% 222
2022
Q1 		– Sell
-7,450
Closed -$671K – 1615
2021
Q4 		$671K Buy
+7,450
New +$637K 0.03% 535
2021
Q3 		– Sell
-53,300
Closed -$4.14M – 1640
2021
Q2 		$4.14M Buy
+53,300
New +$4.04M 0.09% 254
2021
Q1 		– Sell
-40,686
Closed -$6.94M – 1039
2020
Q4 		$6.94M Buy
+40,686
New +$6.03M 0.23% 105

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Ergoteles's SRPT Position: Q3 2023 in Review

Ergoteles sold out of Sarepta Therapeutics (SRPT) in Q3 2023, closing a stake of 23,502 shares — an estimated $2.69M sold.

Ergoteles first reported a position in SRPT in Q4 2020 and held it in 8 quarters. The position peaked at $7.76M in Q4 2022. 394 funds tracked by Wall St. Rank hold SRPT as of Q3 2023.

  • Ergoteles reported no remaining Sarepta Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 23,502 Sarepta Therapeutics shares in Q3 2023, an estimated $2.69M.
  • Ergoteles first reported a position in Sarepta Therapeutics in Q4 2020 and held it in 8 quarters.
  • Ergoteles's Sarepta Therapeutics position peaked at $7.76M in Q4 2022.
  • 394 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.